Cite
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
MLA
Forde, Patrick M., et al. “Durvalumab with Platinum-Pemetrexed for Unresectable Pleural Mesothelioma: Survival, Genomic and Immunologic Analyses from the Phase 2 PrE0505 Trial.” Nature Medicine, vol. 27, no. 11, Nov. 2021, pp. 1910–20. EBSCOhost, https://doi.org/10.1038/s41591-021-01541-0.
APA
Forde, P. M., Anagnostou, V., Sun, Z., Dahlberg, S. E., Kindler, H. L., Niknafs, N., Purcell, T., Santana-Davila, R., Dudek, A. Z., Borghaei, H., Lanis, M., Belcaid, Z., Smith, K. N., Balan, A., White, J. R., Cherry, C., Ashok Sivakumar, I. K., Shao, X. M., Chan, H. Y., … Ramalingam, S. S. (2021). Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature Medicine, 27(11), 1910–1920. https://doi.org/10.1038/s41591-021-01541-0
Chicago
Forde, Patrick M, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E Dahlberg, Hedy L Kindler, Noushin Niknafs, Thomas Purcell, et al. 2021. “Durvalumab with Platinum-Pemetrexed for Unresectable Pleural Mesothelioma: Survival, Genomic and Immunologic Analyses from the Phase 2 PrE0505 Trial.” Nature Medicine 27 (11): 1910–20. doi:10.1038/s41591-021-01541-0.